Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Sponsor: Bedaya Hospital
Summary
The aim of this randomized controlled trial was to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.
Official title: Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial
Key Details
Gender
FEMALE
Age Range
35 Years - 44 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-02
Completion Date
2026-12
Last Updated
2024-01-23
Healthy Volunteers
No
Conditions
Interventions
Progestin primed ovarian stimulation
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
GnRH antagonist
HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.
Locations (1)
Bedaya Hospital
Giza, Egypt